Clinical Trials
4
Active:2
Completed:1
Trial Phases
2 Phases
Phase 1:3
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (75.0%)Phase 2
1 (25.0%)A Beta-only IL-2 ImmunoTherapY Study
Phase 1
Recruiting
- Conditions
- Advanced Solid TumorUnresectable Solid TumorClear Cell Renal Cell CarcinomaTriple Negative Breast CancerNon-Small Cell Lung Cancer SquamousNon-Small Cell Lung Cancer Non-squamousColorectal Cancer (MSI-H)Gastric CancerCervical CancerBasal Cell Carcinoma
- Interventions
- First Posted Date
- 2021-10-21
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- Medicenna Therapeutics, Inc.
- Target Recruit Count
- 115
- Registration Number
- NCT05086692
- Locations
- 🇵🇹
Instituto Portugues De Oncologia Do Porto, Porto, Portugal
🇪🇸Institut Catala d'Oncologia (ICO)-Badalona, Badalona, Spain
🇪🇸Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain
Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma
Phase 2
Completed
- Conditions
- GlioblastomaGlioblastoma MultiformeGrade IV GliomaGrade IV Astrocytoma
- Interventions
- First Posted Date
- 2016-08-08
- Last Posted Date
- 2022-10-24
- Lead Sponsor
- Medicenna Therapeutics, Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT02858895
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, California, United States
🇺🇸Boca Raton Regional Hospital, Boca Raton, Florida, United States
News
No news found